CSIMarket
 
Vyne Therapeutics Inc   (VYNE)
Other Ticker:  
 
 
Price: $2.0100 $-0.05 -2.427%
Day's High: $2.09 Week Perf: -6.07 %
Day's Low: $ 2.00 30 Day Perf: -2.9 %
Volume (M): 39 52 Wk High: $ 8.73
Volume (M$): $ 79 52 Wk Avg: $3.75
Open: $2.09 52 Wk Low: $1.67



 Market Capitalization (Millions $) 7
 Shares Outstanding (Millions) 3
 Employees -
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -28
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Vyne Therapeutics Inc
Vyne Therapeutics Inc. is a biopharmaceutical company that focuses on developing and commercializing therapeutics for the treatment of various eye diseases. The company was founded in 2017 and is headquartered in Irvine, California.

Vyne Therapeutics is committed to developing innovative and effective treatments for eye diseases, using advanced technologies and scientific approaches to address unmet needs in ophthalmology. The company's primary focus is on treating dry eye disease, which affects millions of people worldwide.

The company has developed a pipeline of novel and differentiated drug candidates for the treatment of dry eye disease. These candidates are designed to address the underlying causes of the condition, such as inflammation and oxidative stress, rather than just addressing the symptoms.

One of the key products in Vyne Therapeutics' pipeline is VYN201, a first-in-class anti-inflammatory and anti-oxidant agent. The drug is designed to target multiple pathways involved in the inflammation and oxidative stress associated with dry eye disease, providing a more comprehensive treatment approach than currently available therapies.

Another product in the company's pipeline is VYN202, a small molecule that targets the TRPM8 ion channel. This channel is involved in regulating tear production, and VYN202 is designed to promote tear secretion and reduce dry eye symptoms.

In addition to its novel drug candidates, Vyne Therapeutics also has a strong focus on clinical development and regulatory affairs. The company's team of experienced researchers and clinicians are dedicated to conducting rigorous clinical trials and obtaining regulatory approvals for its products.

Overall, Vyne Therapeutics is a promising biopharmaceutical company that is focused on developing innovative and effective treatments for dry eye disease. With a strong pipeline, experienced team, and commitment to clinical development, the company is well-positioned for future success in the ophthalmology market.


   Company Address: 685 Route 202/206 N, Suite 301 Bridgewater 8807 NJ
   Company Phone Number: 775-7936   Stock Exchange / Ticker: NASDAQ VYNE
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Vyne Therapeutics Inc

Vyne Therapeutics Inc Shines with Remarkable 1166.667% Revenue Growth in Q4 2023 Earnings Report

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, recently announced its financial results for the fourth quarter and year ended December 31, 2023. While the company reported a very solid revenue improvement of 1166.667% year on year to $0.08 million in the fourth quarter, it also experienced widening diminishing returns at -$0.20. However, in comparison to the preceding quarter, there was an improvement in income per share from -$2.01 per share, although revenue tumbled by -33.333% from $0.11 million.
Despite these numbers, VYNE Therapeutics Inc reported a net loss of -$6.188 million in the fourth quarter of 2023, compared to a deficit of -$9.945 million in the same quarter a year ago. Additionally, the company pointed out a net loss of -$28.45 million for the fiscal period of 2023, with revenue totaling $0.42 million. Although VYNE Therapeutics Inc decreased its loss per share to -$2.78 from -$7.28 in the preceding fiscal year, revenue deteriorated by -11.11% from $0.48 million.

Clinical Study

VYNE Therapeutics Makes Striking Progress in Vitiligo Treatment as Phase 1b Trial Results are Unveiled at Prestigious Scientific Symposium

Published Tue, Feb 27 2024 1:01 PM UTC

Bridgewater, N.J. - Innovative clinical-stage biopharmaceutical company, VYNE Therapeutics Inc., has announced that its Chief Scientific Officer, Dr. Iain Stuart, will present groundbreaking findings from the Phase 1b trial of their novel therapy, VYN201, at the highly esteemed 2024 Global Vitiligo Foundation Annual Scientific Symposium. The event, scheduled to take place in...

Clinical Study

BET On It: An Innovative Breakthrough in Nonsegmental Vitiligo Treatment Enabled by Genomic Science

Published Wed, Jan 10 2024 1:00 PM UTC

is pleased to document a milestone advance in the field of immuno-inflammatory conditions. On January 10, 2024, VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company poised at the forefront of medical innovation, disclosed a trove of encouraging biomarker data. These reported results stemmed from their dedicated Phase 1b trial, which explored treatments for non...

Vyne Therapeutics Inc

Vyne Therapeutics Inc Defies Expectations and Sets the Stock Market Ablaze with Astonishing Surge in Shortfall

The stock market has long been a hub of excitement and potential. Investors are constantly on the lookout for companies that are not only performing well financially, but also have a promising outlook for the future. One such company that has caught the attention of many investors is Vyne Therapeutics Inc.
In the most recent fiscal period, Vyne Therapeutics Inc showcased its strength and resilience despite challenging market conditions. The company reported a surge in its shortfall per share, with figures showing an increase from $-0.15 a year ago to $-3.09 per share. Similarly, the prior quarter also witnessed a significant rise in the shortfall from $-1.74 per share. These numbers might appear alarming at first glance, but when put into perspective, they actually signal a positive trend.

Vyne Therapeutics Inc

Vyne Therapeutics Inc's Gloomy Path to Recovery: A Startling Revenue Decline Shakes Investors in Q1 2023 Earnings Season

As an investor in the stock market, it is important to exercise caution when considering investing in a company with a negative return on investment such as Vyne Therapeutics Inc. The company has recorded a cumulative net loss of $-34 million during the 12 months ending in the first quarter of 2023, resulting in an ROI of -81.7%. This is a significant decline from the previous ranking period where the total ranking deteriorated from 0 to 4187. Within the healthcare sector, 617 other companies had a higher ROI.
Furthermore, Vyne Therapeutics Inc reported a shortfall per stock of $-1.74 per share for the fiscal first quarter of 2023 compared to $0.08 a year ago and a surge in shortfall from $-0.17 per share from the preceding reporting period. The company's revenue also decreased by -44.382 % to $0.10 million from $0.18 million in the comparable reporting period a year ago. Although revenue sequentially doubled by 1550% from $0.01 million, Vyne Therapeutics Inc logged a net shortfall of $-5.622 million instead of net proceeds of $4.670 million booked in the comparable reporting period a year before.






 

Vyne Therapeutics Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Vyne Therapeutics Inc does not provide revenue guidance.

Earnings Outlook
Vyne Therapeutics Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com